AbCellera Biologics Inc. ABCL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s additional paid-in capital?
- AbCellera Biologics Inc. (ABCL) reported additional paid-in capital of $196.62M in Q1 2026.
- How has AbCellera Biologics Inc.'s additional paid-in capital changed year-over-year?
- AbCellera Biologics Inc.'s additional paid-in capital increased by 16.6% year-over-year, from $168.6M to $196.62M.
- What is the long-term trend for AbCellera Biologics Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s additional paid-in capital has grown at a 101.8% compound annual growth rate (CAGR), from $5.92M to $198.28M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.